By Jared Foretek (July 11, 2024, 8:15 PM EDT) — A D.C. federal judge on Thursday seemed skeptical about Vanda Pharmaceuticals’ claims that waiting for the U.S. Food and Drug Administration to review its challenge to the agency’s approval of a generic challenger to its sleep medication would seriously jeopardize the company’s future….

Law360 is on it, so you are, too.

A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.

A Law360 subscription includes features such as

• Daily newsletters
• Expert analysis
• Mobile app
• Advanced search
• Judge information
• Real-time alerts
• 450K+ searchable archived articles

And more!

Experience Law360 today with a free 7-day trial.